BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($0.92), $0.07 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $1.87 million versus the consensus estimate of $5.01 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.